Compare ARVN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | TECX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 549.5M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | TECX |
|---|---|---|
| Price | $8.04 | $30.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | $15.05 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 680.3K | 121.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $14.39 |
| 52 Week High | $14.22 | $35.99 |
| Indicator | ARVN | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 58.40 |
| Support Level | $7.35 | $27.31 |
| Resistance Level | $10.18 | $31.39 |
| Average True Range (ATR) | 0.41 | 1.77 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 70.20 | 83.62 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.